Tvardi Posts Q2 Net Income Turnaround
Tvardi Therapeutics (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on developing new therapies for serious diseases, released its second quarter fiscal 2025 results on August 14, 2025. The headline news was a GAAP diluted loss per share of $(1.00), falling short of analyst estimates, which called for a GAAP loss of $(0.68). The EPS miss was driven by higher operating costs, including merger-related professional fees. Net income was $4.2 million, a sharp move from a $7.0 million loss in the prior-year period, though this swing was driven by non-operating gains and not underlying business momentum. Overall, the period captured the volatility typical of newly public biotechs, with operational execution on key clinical trials, but mixed underlying financials relative to expectations.
Source: Analyst estimates for the quarter provided by FactSet.
Tvardi Therapeutics is a biopharmaceutical company researching and developing treatments for conditions such as cancer and lung scarring diseases that currently lack effective therapies. Its pipeline is anchored by TTI-101, a STAT3 inhibitor, which is being developed for idiopathic pulmonary fibrosis (IPF) and liver cancer. TTI-101 is an oral medicine designed to block a key protein involved in disease progression.
Source Fool.com
